~~<i id='82ADF87D05'><strike id='82ADF87D05'><tt id='82ADF87D05'><pre id='82ADF87D05'></pre></tt></strike></i>~~

Home» leisure time» hotspot

hotspot

author：explore 2025-09-28 17:00:33 Page View：446

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： All of Us, NIH's precision medicine initiative, gets a big boost
Next article： Medical records are filled with copy

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

What is microchimerism and how does it affect maternal health?

KristineChuaIllustration:STAT;Courtesy:KristineChuaChimeras—fantasticalcreaturescomposedofdifferenta

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Infant mortality in U.S. rose last year for first time in decades: CDC

APPhoto/EricGayTheU.S.infantmortalityraterose3%lastyear—thelargestincreaseintwodecades,accordingtoth